Expansion opportunity TRI’s recent NIH contract award and significant revenue scale suggest a potential upsell path for expanded CRO+ services, including further clinical development support, regulatory strategy, and program management for larger multi-site studies with public sector sponsors.

Public sector growth With a large NIH contract in 2024 and a recognized status as a fast-growing, diverse-owned CRO+, TRI is well-positioned to target additional government and health agency opportunities, including vaccine, biologic, and medical device programs that require compliant outsourcing partners.

Full-service leverage As a full-service CRO+, TRI combines science, IT, and communication services; sales conversations can emphasize integrated product development pipelines, data management, and cross-functional support to reduce sponsor vendor fragmentation and accelerate timelines.

Mid-market adaptability With a mid-sized client focus and global footprint, TRI can pursue tiered partnerships with medium-to-large sponsors seeking nimble CROs that scale, offering flexible resourcing, schedule-friendly deliverables, and rapid onboarding for new programs.

Digital and tech enablement TRI’s tech stack including iCIMS, Adobe Experience Cloud, SharePoint Online, and IT-driven capabilities presents an opportunity to position TRI as a modernized outsourcing partner capable of streamlined collaboration, tighter reporting, and robust data security for complex trials.